Health
Synairgen boss says SNG001 results “a clearer signal than we could have dared hope for” – Proactive Investors UK
On Monday, the company reported that patients who received its treatment had a 79% lower risk of developing severe disease compared to those given the placebo
On Monday, the company reported that patients who received its treatment had a 79% lower risk of developing severe disease compared to those given the placeboSynairgen PLCs (LON:SNG) chief executive Richard Marsden has said that the results from the companys latest trial of its SNG001 treatment for coronavirus are a clearer signal then we could have dared to hope for.
On Monday, the company reported that patients who received SNG001, an inhaled formulation of interferon beta, had a 79% lower ri…
Continue Reading